Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease

Current Pharmaceutical Biotechnology

Volumn 12, Issue 5, 2011, Pages 765-773

  Chaparro, María ^a   Gisbert, Javier P ^a  

^a Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas   (Spain)

Author keywords

Adalimumab; Azathioprine; Inflammatory bowel disease; Infliximab; Mercaptopurine; Methotrexate; Pregnancy

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; STEROID;

BIOLOGICAL THERAPY; CONGENITAL MALFORMATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; HUMAN; PLACENTA FUNCTION; PLACENTAL TRANSFER; PREGNANCY; REVIEW; ULCERATIVE COLITIS;

EID: 79955601056     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111795470903     Document Type: Review

References (108)

1. Gedeon, C.; Koren, G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta, 2006, 27(8), 861-868.
2. Subhani, J.M.; Hamiliton, M.I. Review article: The management of inflammatory bowel disease during pregnancy. Aliment. Pharmacol. Ther., 1998, 12(11), 1039-1053.
3. Connell, W.; Miller, A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf., 1999, 21(4), 311-323.
4. Munkholm, P. Pregnancy, fertility, and disease course in patients with Crohn's disease and ulcerative colitis. Eur. J. Intern. Med., 2000, 11(4), 215-221.
5. Katz, J.A.; Pore, G. Inflammatory bowel disease and pregnancy. Inflamm. Bowel Dis., 2001, 7(2), 146-157.
6. Alstead, E. Fertility and pregnancy in inflammatory bowel disease. World J. Gastroenterol., 2001, 7(4), 455-459.
7. Alstead, E.M. Inflammatory bowel disease in pregnancy. Postgrad. Med. J., 2002, 78(915), 23-26.
8. Lamah, M.; Scott, H.J. Inflammatory bowel disease and pregnancy. Int. J. Colorectal Dis., 2002, 17(4), 216-222.
9. Alstead, E.M.; Nelson-Piercy, C. Inflammatory bowel disease in pregnancy. Gut, 2003, 52(2), 159-161.
10. Kane, S. Inflammatory bowel disease in pregnancy. Gastroenterol. Clin. North Am., 2003, 32(1), 323-340.
11. Steinlauf, A.F.; Present, D.H. Medical management of the pregnant patient with inflammatory bowel disease. Gastroenterol. Clin. North Am., 2004, 33(2), 361-385.
12. Ferrero, S.; Ragni, N. Inflammatory bowel disease: management issues during pregnancy. Arch. Gynecol. Obstet., 2004, 270(2), 79-85.
13. Katz, J.A. Pregnancy and inflammatory bowel disease. Curr. Opin. Gastroenterol., 2004, 20(4), 328-332.
14. Sauk, J.; Kane, S. The use of medications for inflammatory bowel disease during pregnancy and nursing. Expert Opin. Pharmacother., 2005, 6(11), 1833-1839.
15. Mahadevan, U.; Kane, S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology, 2006, 131(1), 283-311.
16. Moffatt, D.C.; Bernstein, C.N. Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. Best Pract. Res. Clin. Gastroenterol., 2007, 21(5), 835-847.
17. Mottet, C.; Juillerat, P.; Pittet, V.; Gonvers, J.J.; Froehlich, F.; Vader, J.P.; Michetti, P.; Felley, C. Pregnancy and breastfeeding in patients with Crohn's disease. Digestion, 2007, 76(2), 149-160.
18. Gisbert, J.P.; Gomollon, F. [Common errors in the management of outpatients with inflammatory bowel disease]. Gastroenterol. Hepatol., 2007, 30(8), 469-486.
19. Habal, F.M.; Ravindran, N.C. Management of inflammatory bowel disease in the pregnant patient. World J. Gastroenterol., 2008, 14(9), 1326-1332.
20. Ferguson, C.B.; Mahsud-Dornan, S.; Patterson, R.N. Inflammatory bowel disease in pregnancy. BMJ, 2008, 337, a427.
21. Habal, F.M.; Kapila, V. Inflammatory bowel disease and pregnancy: evidence, uncertainty and patient decision-making. Can. J. Gastroenterol., 2009, 23(1), 49-53.
22. Gisbert, J.P. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm. Bowel Dis., 2010, 16(5), 881-895.
23. Cornish, J.; Tan, E.; Teare, J.; Teoh, T.G.; Rai, R.; Clark, S.K.; Tekkis, P.P. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut, 2007, 56(6), 830-837.
24. Kornfeld, D.; Cnattingius, S.; Ekbom, A. Pregnancy outcomes in women with inflammatory bowel disease--a population-based cohort study. Am. J. Obstet. Gynecol., 1997, 177(4), 942-946.
25. Mahadevan, U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut, 2006, 55(8), 1198-1206.
26. van der Aa, E.M.; Peereboom-Stegeman, J.H.; Noordhoek, J.; Gribnau, F.W.; Russel, F.G. Mechanisms of drug transfer across the human placenta. Pharm. World Sci., 1998, 20(4), 139-148.
27. Enders, A.C.; Blankenship, T.N. Comparative placental structure. Adv. Drug Deliv. Rev., 1999, 38(1), 3-15.
28. Pacifici, G.M.; Nottoli, R. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet., 1995, 28(3), 235-269.
29. Syme, M.R.; Paxton, J.W.; Keelan, J.A. Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet., 2004, 43(8), 487-514.
30. Hill, M.D.; Abramson, F.P. The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state. Clin. Pharmacokinet., 1988, 14(3), 156-170.
31. Forestier, F.; Daffos, F.; Capella-Pavlovsky, M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound. Thromb. Res., 1984, 34(6), 557-560.
32. Paxton, J.W. Alpha 1-acid glycoprotein and binding of basic drugs. Methods Find. Exp. Clin. Pharmacol., 1983, 5(9), 635-648.
33. Kragh-Hansen, U. Molecular aspects of ligand binding to serum albumin. Pharmacol. Rev., 1981, 33(1), 17-53.
34. Sastry, B.V. Techniques to study human placental transport. Adv. Drug Deliv. Rev., 1999, 38(1), 17-39.
35. Hahn, T.; Desoye, G. Ontogeny of glucose transport systems in the placenta and its progenitor tissues. Early Pregnancy, 1996, 2(3), 168-182.
36. Moe, A.J. Placental amino acid transport. Am. J. Physiol., 1995, 268(6 Pt 1), C1321-1331.
37. Gottesman, M.M.; Hrycyna, C.A.; Schoenlein, P.V.; Germann, U.A.; Pastan, I. Genetic analysis of the multidrug transporter. Annu. Rev. Genet., 1995, 29, 607-649.
38. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
39. Ganapathy, V.; Prasad, P.D.; Ganapathy, M.E.; Leibach, F.H. Placental transporters relevant to drug distribution across the maternalfetal interface. J. Pharmacol. Exp. Ther., 2000, 294(2), 413-420.
40. Lankas, G.R.; Wise, L.D.; Cartwright, M.E.; Pippert, T.; Umbenhauer, D.R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol., 1998, 12(4), 457-463.
41. Smit, J.W.; Huisman, M.T.; van Tellingen, O.; Wiltshire, H.R.; Schinkel, A.H. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest., 1999, 104(10), 1441-1447.
42. König, J.; Nies, A.T.; Cui, Y.; Leier, I.; Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta, 1999, 1461(2), 377-394.
43. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, 92(16), 1295-1302.
44. St-Pierre, M.V.; Serrano, M.A.; Macias, R.I.; Dubs, U.; Hoechli, M.; Lauper, U.; Meier, P.J.; Marin, J.J. Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279(4), R1495-R1503.
45. Cui, Y.; König, J.; Buchholz, J.K.; Spring, H.; Leier, I.; Keppler, D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 1999, 55(5), 929-937.
46. Liggins, G.C. Premature delivery of foetal lambs infused with glucocorticoids. J. Endocrinol., 1969, 45(4), 515-523.
47. Spinillo, A.; Capuzzo, E.; Ometto, A.; Stronati, M.; Baltaro, F.; Iasci, A. Value of antenatal corticosteroid therapy in preterm birth. Early Hum. Dev., 1995, 42(1), 37-47.
48. Ward, R.M. Pharmacologic enhancement of fetal lung maturation. Clin. Perinatol., 1994, 21(3), 523-542.
49. Ballard, P.L.; Ballard, R.A. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am. J. Obstet. Gynecol., 1995, 173(1), 254-262.
50. Crowley, P.; Chalmers, I.; Keirse, M.J. The effects of corticosteroid administration before preterm delivery: an overview of the evidence from controlled trials. Br. J. Obstet. Gynaecol., 1990, 97(1), 11-25.
51. Varma, D.R. Investigation of the maternal to foetal serum concentration gradient of dexamethasone in the rat. Br. J. Pharmacol., 1986, 88(4), 815-820.
52. Maillefert, J.F.; Duchamp, O.; Solary, E.; Genne, P.; Tavernier, C. Effects of cyclosporin at various concentrations on dexamethasone intracellular uptake in multidrug resistant cells. Ann. Rheum. Dis., 2000, 59(2), 146-148.
53. Pearson, D.C.; May, G.R.; Fick, G.; Sutherland, L.R. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev., 2000, 2, CD000067.
54. Gisbert, J.P.; Linares, P.M.; McNicholl, A.G.; Maté, J.; Gomollón, F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment. Pharmacol. Ther., 2009, 30(2), 126-137.
55. Polifka, J.E.; Friedman, J.M. Teratogen update: azathioprine and 6-mercaptopurine. Teratology, 2002, 65(5), 240-261.
56. Voogd, C.E. Azathioprine, a genotoxic agent to be considered nongenotoxic in man. Mutat. Res., 1989, 221(2), 133-152.
57. Mosesso, P.; Palitti, F. The genetic toxicology of 6-mercaptopurine. Mutat. Res., 1993, 296(3), 279-294.
58. Bermas, B.L.; Hill, J.A. Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum., 1995, 38(12), 1722-1732.
59. Platzek, T.; Bochert, G. Dose-response relationship of teratogenicity and prenatal-toxic risk estimation of 6-mercaptopurine riboside in mice. Teratog. Carcinog. Mutagen., 1996, 16(3), 169-181.
60. Alstead, E.M.; Ritchie, J.K.; Lennard-Jones, J.E.; Farthing, M.J.; Clark, M.L. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology, 1990, 99(2), 443-446.
61. Hou, S. Pregnancy in renal transplant recipients. Adv. Ren. Replace. Ther., 2003, 10(1), 40-47.
62. Lémann, M.; Mary, J.Y.; Colombel, J.F.; Duclos, B.; Soule, J.C.; Lerebours, E.; Modigliani, R.; Bouhnik, Y.; Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology, 2005, 128(7), 1812-1818.
63. Treton, X.; Bouhnik, Y.; Mary, J.Y.; Colombel, J.F.; Duclos, B.; Soule, J.C.; Lerebours, E.; Cosnes, J.; Lemann, M. Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin. Gastroenterol. Hepatol., 2009, 7(1), 80-85.
64. Friedman, S. Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients? Am. J. Gastroenterol., 2007, 102(7), 1414-1416.
65. Zlatanic, J.; Korelitz, B.I.; Rajapakse, R.; Kim, P.S.; Rubin, S.D.; Baiocco, P.J.; Panagopoulos, G. Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease. J. Clin. Gastroenterol., 2003, 36(4), 303-309.
66. Saarikoski, S.; Seppälä, M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am. J. Obstet. Gynecol., 1973, 115(8), 1100-1106.
67. Estlin, E.J. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine. Cancer Treat. Rev., 2001, 27(6), 351-363.
68. Platzek, T.; Schwabe, R.; Rahm, U.; Bochert, G. DNA modification induced by 6-mercaptopurine riboside in murine embryos. Chem. Biol. Interact., 1994, 93(1), 59-71.
69. Matalon, S.T.; Ornoy, A.; Lishner, M. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod. Toxicol., 2004, 18(2), 219-230.
70. Furukawa, S.; Usuda, K.; Abe, M.; Hayashi, S.; Ogawa, I. Effect of 6-mercaptopurine on rat placenta. J. Vet. Med. Sci., 2008, 70(6), 551-556.
71. Kremer, J.M. Toward a better understanding of methotrexate. Arthritis Rheum., 2004, 50(5), 1370-1382.
72. Al-Saleh, E.; Al-Harmi, J.; Al-Rashdan, I.; Al-Shammari, M.; Nandakumaran, M. Maternal-fetal transport kinetics of methotrexate in perfused human placenta: In vitro study. J. Matern. Fetal Neonatal Med., 2007, 20(5), 411-418.
73. Lichtiger, S.; Present, D.H.; Kornbluth, A.; Gelernt, I.; Bauer, J.; Galler, G.; Michelassi, F.; Hanauer, S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med., 1994, 330(26), 1841-1845.
74. García-López, S.; Gomollón-García, F.; Pérez-Gisbert, J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol. Hepatol., 2005, 28(10), 607-614.
75. Anderson, J.B.; Turner, G.M.; Williamson, R.C. Fulminant ulcerative colitis in late pregnancy and the puerperium. J. R. Soc. Med., 1987, 80(8), 492-494.
76. Armenti, V.T.; Ahlswede, K.M.; Ahlswede, B.A.; Jarrell, B.E.; Moritz, M.J.; Burke, J.F. National transplantation Pregnancy Registry--outcomes of 154 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation, 1994, 57(4), 502-506.
77. Armenti, V.T.; Radomski, J.S.; Moritz, M.J.; Gaughan, W.J.; Gulati, R.; McGrory, C.H.; Coscia, L.A. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin. Transpl., 2005, 69-83.
78. Bar Oz, B.; Hackman, R.; Einarson, T.; Koren, G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation, 2001, 71(8), 1051-1055.
79. Bourget, P.; Fernandez, H.; Bismuth, H.; Papiernik, E. Transplacental passage of cyclosporine after liver transplantation. Transplantation, 1990, 49(3), 663.
80. Hanauer, S.B.; Feagan, B.G.; Lichtenstein, G.R.; Mayer, L.F.; Schreiber, S.; Colombel, J.F.; Rachmilewitz, D.; Wolf, D.C.; Olson, A.; Bao, W.; Rutgeerts, P.; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359(9317), 1541-1549.
81. Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S.B.; Lichtenstein, G.R.; de Villiers, W.J.; Present, D.; Sands, B.E.; Colombel, J.F. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med., 2005, 353(23), 2462-2476.
82. Gisbert, J.P.; González-Lama, J.; Maté, J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment. Pharmacol. Ther., 2007, 25(1), 19-37.
83. Rychly, D.J.; DiPiro, J.T. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy, 2005, 25(9), 1181-1192.
84. Lichtenstein, G.R.; Feagan, B.G.; Cohen, R.D.; Salzberg, B.A.; Diamond, R.H.; Chen, D.M.; Pritchard, M.L.; Sandborn, W.J. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol., 2006, 4(5), 621-630.
85. Katz, J.A.; Antoni, C.; Keenan, G.F.; Smith, D.E.; Jacobs, S.J.; Lichtenstein, G.R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol., 2004, 99(12), 2385-2392.
86. Colombel, J.F. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. Expert Rev. Gastroenterol. Hepatol., 2008, 2(2), 163-176.
87. Baker, D.E. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord., 2004, 4(4), 196-210.
88. Carter, J.D.; Ladhani, A.; Ricca, L.R.; Valeriano, J.; Vasey, F.B. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol., 2009, 36(3), 635-641.
89. Roux, C.H.; Brocq, O.; Breuil, V.; Albert, C.; Euller-Ziegler, L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford), 2007, 46(4), 695-698.
90. Berthelot, J.M.; De Bandt, M.; Goupille, P.; Solau-Gervais, E.; Lioté, F.; Goeb, V.; Azaïs, I.; Martin, A.; Pallot-Prades, B.; Maugars, Y.; Mariette, X.; CRI (Club Rhumatismes et Inflammation). Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine, 2009, 76(1), 28-34.
91. Vesga, L.; Terdiman, J.P.; Mahadevan, U. Adalimumab use in pregnancy. Gut, 2005, 54(6), 890.
92. Mishkin, D.S.; Van Deinse, W.; Becker, J.M.; Farraye, F.A. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm. Bowel Dis., 2006, 12(8), 827-828.
93. Coburn, L.A.; Wise, P.E.; Schwartz, D.A. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig. Dis. Sci., 2006, 51(11), 2045-2047.
94. Sandborn, W.J.; Feagan, B.G.; Stoinov, S.; Honiball, P.J.; Rutgeerts, P.; Mason, D.; Bloomfield, R.; Schreiber, S. PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med., 2007, 357(3), 228-238.
95. Schreiber, S.; Khaliq-Kareemi, M.; Lawrance, I.C.; Thomsen, O. Ø.; Hanauer, S.B.; McColm, J.; Bloomfield, R.; Sandborn, W.J.; PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med., 2007, 357(3), 239-250.
96. Oussalah, A.; Bigard, M.A.; Peyrin-Biroulet, L. Certolizumab use in pregnancy. Gut, 2009, 58(4), 608.
97. Mix, E.; Goertsches, R.; Zett, U.K. Immunoglobulins--basic considerations. J. Neurol., 2006, 253(Suppl 5), V9-V17.
98. Saji, F.; Samejima, Y.; Kamiura, S.; Koyama, M. Dynamics of immunoglobulins at the feto-maternal interface. Rev. Reprod., 1999, 4(2), 81-89.
99. Takizawa, T.; Anderson, C.L.; Robinson, J.M. A novel Fc gamma R-defined, IgG-containing organelle in placental endothelium. J. Immunol., 2005, 175(4), 2331-2339.
100. Pentsuk, N.; van der Laan, J.W. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. B Dev. Reprod. Toxicol., 2009, 86(4), 328-344.
101. Malek, A. Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine, 2003, 21(24), 3362-3364.
102. Story, C.M.; Mikulska, J.E.; Simister, N.E. A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus. J. Exp. Med., 1994, 180(6), 2377-2381.
103. Roopenian, D.C.; Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 2007, 7(9), 715-725.
104. Israel, E.J.; Simister, N.; Freiberg, E.; Caplan, A.; Walker, W.A. Immunoglobulin G binding sites on the human foetal intestine: a possible mechanism for the passive transfer of immunity from mother to infant. Immunology, 1993, 79(1), 77-81.
105. Bright, N.A.; Ockleford, C.D. Cytotrophoblast cells: a barrier to maternofetal transmission of passive immunity. J. Histochem. Cytochem., 1995, 43(9), 933-944.
106. Gurevich, P.; Elhayany, A.; Ben-Hur, H.; Moldavsky, M.; Szvalb, S.; Zandbank, J.; Shperling, I.; Zusman, I. An immunohistochemical study of the secretory immune system in human fetal membranes and decidua of the first trimester of pregnancy. Am. J. Reprod. Immunol., 2003, 50(1), 13-19.
107. Stephens, P.; Nesbitt, A.; Foulkes, R. Placental transfer of the anti-TNF antibody TN3 in rats: comparison of immunoglobulin G1 and pegylated Fab versions. Gut, 2006, 55(Suppl.), A8.
108. Hou, J.K.; Mahadevan, U. A 24-year-old pregnant woman with inflammatory bowel disease. Clin. Gastroenterol. Hepatol., 2009, 7(9), 944-947.